|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||8.80 / 87.93|
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
As is so often the case, the bears are unable to close the deal when it looks like they have an edge.
Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.
We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
What does the upside or the downside look like?
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
The stock purchases by the insiders are at companies developing treatments for breast cancer and schizophrenia.
Let's look at the charts and indicators to come up with a formula for success.
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
The key to dealing with this environment is to keep an open mind.
VenBio gained four seats on Immunomedics' board of directors.
The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.
Immunomedics has been for sale for quite some time, but there hasn't been any interest in it. Here's why.